Skip to main content
Premium Trial:

Request an Annual Quote

Namocell, OLS OMNI Life Science Sign European Distribution Agreement

NEW YORK – Namocell said on Thursday that it has signed an agreement with Germany-based manufacturer OLS OMNI Life Science to distribute Namocell's Single Cell Dispensers in Germany and Austria.

NamoCell's microfluidic-based cell platform dispenses single cells into a 96-well plate in less than a minute.

Financial details of the agreement were not disclosed.

Namocell's "single cell isolation instruments are a game-changer for cell line engineering and development, CRISPR, single-cell genomics, antibody development and other single-cell applications," Andreas Friese, chief operating officer of OLS, said in a statement. "We look forward to offering an expanded cell research portfolio to further strengthen our position as a partner in cell research."

Namocell previously signed an agreement with Takara Bio and HepaTx in February 2020 to apply the Single-Cell Dispenser tool for single-cell genomics for late-stage liver disease.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.